

I Biomarker & Test Menu

October 2020

HistoGeneX offers a full range of services in immunohistochemistry (IHC), immunofluorescence (IF), *in situ* hybridization (ISH) and cytogenetics, and genomics.

We service the pharmaceutical companies, biotech companies, *in vitro* diagnostic manufacturers, academic institutions, and hospitals.

Immunohistochemistry (IHC) Markers

3MeH3K27	CD16	CD68	FAP	MHC-1	PD-1	STING
ALK	CD163	CD79b	FoxP3	MLH1	PD-L1 (22C3)	synaptophysin
AR	CD1a	CD8	HER2	MP0	PD-L1 (28-8)	TIGIT
b2M	CD20	CEA	HER3	MSH2	PD-L1 (SP142)	TIM-3
B7-H3	CD3	chromogranin	HercepTest	MSH6	PD-L1 (SP263)	TUNEL
B7-H4	CD30	cMET	HLA-DR	MUC2	phospho EGFR	VEGF-A
β-catenin	CD31	cMYC	HLA-E	MUM1	phospho ERK	VEGF-R2
Bcl-2	CD34	cPARP	ICOS	OX40	phospho PRAS40	Vimentin
Bcl-6	CD38	cyclin D1	IDO	p16	phospho S6	
CA IX	CD4	desmin	IRF	p53	PMS2	
CD10	CD45	E-cadherin	Ki67	pan Melan	PR	
CD11b	CD45R0	EGFR	LAG-3	panCK	PTEN	
CD138	CD56	ER	mdm2	panTRK	ROS1	

Multiplex IHC & Immunofluorescence (IF) Markers

CD20/PAX5	CD8/GZMB/FoxP3	Dendritic cell IF 4-plex	PD-L1 (SP263)/CD68
CD3/FoxP3	CD8/Ki67	MDSC Ultimapper (Ultivue)	CD39/CD8/panCK
CD31/aSMA	CK5/GATA-3	panCK/CD8	CD138/CD8
CD8/GZMB			

DNA & mRNA *In Situ* Hybridization (ISH) Markers

9p24.1 (PD-L1)	BCL6	EBV (EBER)	MYC
ALK	CLL	HER2	ROS1
BCL2	cMET	HPV	UroVysion
BCL2/CEP18			

****Biomarkers in development****

Genomic Testing

DNA Services

- DNA Extraction using state-of-the-art methods (incl. dual extraction)
- DNA Concentration Measurement
- Mutation Analysis
 - Single Target Mutation
 - Targeted NGS panels
 - Tumor Mutational Burden (TMB) – available Q2 2021
 - Whole Exome Sequencing (WES) – available Q2 2021
- Methylation
- Microsatellite instability (MSI)
 - Idylla™ MSI assay (IVD label)
 - Promega™ MSI assay V1.2

RNA Services

- RNA Extraction using state-of-the-art methods (incl. dual extraction)
- RNA Concentration Measurement
- Expression analysis
 - Bulk and targeted mRNA-Seq
 - Single cell mRNA-Seq – available Q3 2021
 - RT-qPCR
 - NanoString™
 - nCounter® Gene Expression Panels
 - PanCancer IO 360™ Gene Expression Panels (750 cancer-related genes)
 - PanCancer Immune Profiling Panels (770 immune profiling genes)
 - PanCancer Progression Panels (770 genes involved in cancer progression)
 - PanCancer Pathway Panels (770 genes for essential cancer pathways)
 - miRNA Expression Panel
 - nCounter Human v3 miRNA (>800 miRNAs)
 - nCounter Vantage 3D RNA Fusion Panel
 - Lung RNA Fusion Panel (63 probes)
 - nCounter-based Lymphoma Subtyping Test (LST) for Cell-of-Origin (COO)
 - nPAM50 Breast Cancer Subtyping Assay
- NGS based mutation, fusion, and CNV detection

HistoGeneX Laboratories continually develop new biomarker tests.

Contact us for any custom development of your assays.

For more information, please contact HistoGeneX at:

Email: bd@histogenex.com

Tel: +32 (0)3 502 05 06 (Belgium)

Tel: +1 630 473 66 95 (USA)

Globally Integrated Labs

